DNAYTelesis Bio Inc.

Nasdaq codexdna.com


$ 0.31 $ 0.02 (6.63 %)    

Wednesday, 24-Apr-2024 11:48:27 EDT
QQQ $ 433.04 $ 1.75 (0.41 %)
DIA $ 383.81 $ 1.49 (0.39 %)
SPY $ 510.06 $ 1.80 (0.35 %)
TLT $ 88.99 $ 0.74 (0.84 %)
GLD $ 213.96 $ 0.00 (0 %)
$ 0.3395
$ 0.32
$ 0.37 x 100
$ 0.34 x 100
$ 0.31 - $ 0.32
$ 0.30 - $ 3.01
25,552
na
10.13M
$ 0.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-29-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-22-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-23-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stocks-that-hit-52-week-lows-on-wednesday

  Wednesday saw 219 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  Tuesday's session saw 167 companies set new 52-week lows.

 keybanc-maintains-overweight-on-codex-dna-lowers-price-target-to-5

Keybanc analyst Paul Knight maintains Codex DNA (NASDAQ:DNAY) with a Overweight and lowers the price target from $8 to $5.

 telesis-bio-raises-fy22-revenue-outlook-to-23m---25m-from-22m---24m-vs-2115m-estimate

Updated 2022 Financial Guidance The following statements are based on Telesis Bio's current expectations for fiscal 2022. ...

 telesis-bio-q3-eps-042-beats-048-estimate-sales-668m-beat-530m-estimate

Telesis Bio (NASDAQ:DNAY) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.48) b...

 earnings-scheduled-for-november-8-2022

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenu...

 telesis-bio-and-cellibre-announce-collaboration-to-optimize-development-of-future-bioxp-dbc-instrument

Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufactur...

 codex-dna-announces-plan-to-change-corporate-name-to-telesis-bio

Codex DNA, Inc. (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to chan...

 codex-dna-expands-application-of-proprietary-error-correction-technology

Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of...

 12-health-care-stocks-moving-in-tuesdays-pre-market-session

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. T...

 11-health-care-stocks-moving-in-wednesdays-pre-market-session

  Gainers  

 codex-dna-q2-earnings-insights
Codex DNA: Q2 Earnings Insights
08/10/2022 03:09:03

  Codex DNA (NASDAQ:DNAY) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors ...

 codex-dna-q2-eps-050-beats-051-estimate-sales-566m-beat-445m-estimate

Codex DNA (NASDAQ:DNAY) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.51) by ...

 earnings-scheduled-for-august-9-2022

  Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second q...

 stocks-that-hit-52-week-lows-on-friday

  On Friday, 137 stocks made new 52-week lows.

 this-technology-stock-is-down-by-over-11-heres-26-stocks-moving-premarket

Gainers FedNat Holding Company (NASDAQ: FNHC) rose 32.3% to $0.4764 in pre-market trading after jumping over 16% on Friday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION